SecSonar.com

GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

GeneDx Holdings Corp. (WGS) is a Medical - Healthcare Information Services company based in US with a market capitalization of $1.5B. Revenue grew 40.0% year-over-year and the company generated $14.3M in free cash flow. This page tracks WGS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1K employees · IPO Nov 4, 2020

Valuation

Valuation & price

$40.75 · as of May 17, 2026 · -75.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.96

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$168$101$34.71Jul 25Dec 25Jul 26Jul 7, 25$85.74Jul 9, 25$91.88Jul 11, 25$82.56Jul 15, 25$81.69Jul 17, 25$80.42Jul 21, 25$78.35Jul 23, 25$82.95Jul 25, 25$79.83Jul 29, 25$91.78Jul 31, 25$101.95Aug 4, 25$108.35Aug 6, 25$105.85Aug 11, 25$110.54Aug 13, 25$123.11Aug 15, 25$126.36Aug 19, 25$120.65Aug 21, 25$120.72Aug 25, 25$121.87Aug 27, 25$129.19Aug 29, 25$129.49Sep 3, 25$127.22Sep 5, 25$132.54Sep 9, 25$125.97Sep 11, 25$125.89Sep 16, 25$121.37Sep 18, 25$130.71Sep 22, 25$129.79Sep 24, 25$114.22Sep 26, 25$117.21Sep 30, 25$107.74Oct 2, 25$117.37Oct 6, 25$120.19Oct 8, 25$122.69Oct 10, 25$121.72Oct 14, 25$122.11Oct 16, 25$118.42Oct 21, 25$121.77Oct 23, 25$125.07Oct 27, 25$130.66Oct 29, 25$131.76Oct 31, 25$136.91Nov 4, 25$139.49Nov 6, 25$138.70Nov 10, 25$142.62Nov 12, 25$136.44Nov 14, 25$128.06Nov 18, 25$126.92Nov 20, 25$134.09Nov 25, 25$167.52Nov 28, 25$166.95Dec 2, 25$160.60Dec 4, 25$161.95Dec 8, 25$159.80Dec 10, 25$158.57Dec 12, 25$151.51Dec 16, 25$141.72Dec 18, 25$136.32Dec 22, 25$140.17Dec 24, 25$136.09Dec 29, 25$129.34Jan 2, 26$132.30Jan 6, 26$135.80Jan 8, 26$137.47Jan 12, 26$119.24Jan 14, 26$104.56Jan 16, 26$108.08Jan 21, 26$100.04Jan 23, 26$101.35Jan 27, 26$96.01Jan 29, 26$98.16Feb 2, 26$99.01Feb 4, 26$85.35Feb 9, 26$91.24Feb 11, 26$91.44Feb 13, 26$90.15Feb 18, 26$92.04Feb 20, 26$82.06Feb 24, 26$80.70Feb 26, 26$81.38Mar 2, 26$74.20Mar 4, 26$79.47Mar 6, 26$88.11Mar 10, 26$88.84Mar 12, 26$76.85Mar 17, 26$75.50Mar 19, 26$73.00Mar 23, 26$72.14Mar 25, 26$66.95Mar 27, 26$57.09Mar 31, 26$64.22Apr 2, 26$66.20Apr 7, 26$66.89Apr 9, 26$60.05Apr 13, 26$60.98Apr 15, 26$67.46Apr 17, 26$65.96Apr 22, 26$69.83Apr 24, 26$68.53Apr 28, 26$66.07Apr 30, 26$62.89May 4, 26$67.93May 6, 26$34.71May 8, 26$40.77May 12, 26$39.49May 14, 26$38.85May 18, 26$42.69May 20, 26$44.73May 22, 26$47.31May 28, 26$50.15Jun 1, 26$52.00Jun 3, 26$53.02Jun 5, 26$52.21Jun 9, 26$56.33Jun 11, 26$60.99Jun 15, 26$61.32Jun 17, 26$56.42Jun 22, 26$55.42Jun 24, 26$63.54Jun 26, 26$69.82Jul 2, 26$67.87
$34.5152-week range$167.52
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

40.0%

Revenue growth (YoY)

69.7%

Gross margin

$14.3M

Free cash flow (USD)

-$19.3M

Net debt

Net cash position

0.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$196.2MFY 2020$179.3MFY 2021$212.2MFY 2022$234.7MFY 2023$202.6MFY 2024$305.4MFY 2025$427.5M
$196.2M$427.5M

Free cash flow by year

2019 → 2025

FY 2019$-34.2MFY 2020$-125.1MFY 2021$-211.2MFY 2022$-333.5MFY 2023$-185.9MFY 2024$-34.0MFY 2025$14.3M
-$34.2M$14.3M

Gross margin by year

2021 → 2025

FY 2021-7.8%FY 2022-11.4%FY 202344.4%FY 202463.6%FY 202569.7%
-7.8%69.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

4

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 23, 2026Filing
  • Insider sellInsider Sell $638KStueland Katherine · Director, CHIEF EXECUTIVE OFFICER · $638.1KJun 18, 2026Filing
  • Insider sellInsider Sell $227KFeeley Kevin · CHIEF FINANCIAL OFFICER · $226.6KJun 18, 2026Filing
  • 8-K eventPresident AppointmentJun 16, 2026Filing
  • Insider sellInsider Sell $196KStueland Katherine · Director, CHIEF EXECUTIVE OFFICER · $195.7KJun 11, 2026Filing
  • Insider sellInsider Sell $68KFeeley Kevin · CHIEF FINANCIAL OFFICER · $68.1KJun 11, 2026Filing
  • Insider buyInsider Buy $11.1MCasdin Capital, LLC · Director, 10% Owner · $11.1MJun 8, 2026Filing
  • Insider sellInsider Sell $19KFeeley Kevin · CHIEF FINANCIAL OFFICER · $19.1KJun 3, 2026Filing
  • Insider buyInsider Buy $21.5MCasdin Capital, LLC · Director, 10% Owner · $21.5MMay 20, 2026Filing
  • Insider buyInsider Buy $13.8MMeister Keith A. · Director, 10% Owner · $13.8MMay 15, 2026Filing

Questions

Frequently asked questions

What is GeneDx Holdings Corp.'s market cap?

GeneDx Holdings Corp. (WGS) has a market capitalization of $1.5B.

What is WGS's P/E ratio?

A meaningful P/E ratio is not available for WGS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is WGS's price-to-book (P/B) ratio?

WGS trades at 4.96 times book value per share.

Are insiders buying WGS stock?

Yes — SEC Form 4 filings show 4 open-market insider buys and 7 sells at GeneDx Holdings Corp. in the last 90 days.

Same arena

Related companies in Medical - Healthcare Information Services

TDOC

Teladoc Health, Inc.

$1.4B

SDGR

Schrödinger, Inc.

$1.1B

OMDA

Omada Health

$1.1B

OMCL

Omnicell, Inc.

$2B

GDRX

GoodRx Holdings, Inc.

$1B

PGNY

Progyny, Inc.

$2B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.